Achieve Life Sciences (ACHV) vs Lantheus (LNTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Achieve Life Sciences (ACHV) has outperformed Lantheus (LNTH) over the past year, gaining 108.4% versus a gain of 87.0%. Over five years, LNTH leads with a +330.4% price change compared with -10.7% for ACHV. Lantheus is the larger company by market cap ($6.54 billion vs $741.3 million), about 8.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | LNTH |
|---|---|---|
| Share price | $7.19 | $100.12 |
| Market cap | $741.31M | $6.54B |
| 1-day change | -0.69% | -0.06% |
| YTD return | +44.67% | +50.44% |
| 1-year return | +108.41% | +86.97% |
| 5-year return | -10.68% | +330.44% |
| P/E ratio (TTM) | — | 24.24 |
| Forward P/E | — | 15.70 |
| EPS (TTM) | $-1.69 | $4.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.54B |
| Revenue growth (YoY) | — | +0.50% |
| Net income (latest FY) | — | $233.56M |
| Gross margin | — | 61.10% |
| Operating margin | — | 20.16% |
| Net margin | — | 15.15% |
| 52-week high | $8.64 | $111.86 |
| 52-week low | $2.62 | $50.16 |
| Distance from 52-week high | -16.78% | -10.50% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +96.80% | +7.61% |
| Average volume | 1.43M | 1.32M |
| Shares outstanding | 103.10M | 65.30M |
| Employees | 28 | 1,193 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lantheus is about 8.8 times larger than Achieve Life Sciences by market value ($6.54B vs $741.31M).
- ACHV has outperformed LNTH by 21.4 percentage points over the past year.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
About Lantheus
LNTH stock →Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees
ACHV vs LNTH FAQ
Which is bigger, Achieve Life Sciences or Lantheus?
Lantheus (LNTH) is larger, with a market capitalization of $6.54B compared with $741.31M for Achieve Life Sciences (ACHV).
Which stock has performed better over the past year, ACHV or LNTH?
ACHV returned +108.41% over the past 12 months, compared with +86.97% for LNTH (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and Lantheus in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.